眼科 ›› 2021, Vol. 30 ›› Issue (2): 81-84.doi: 10.13281/j.cnki.issn.1004-4469.2021.02.001

• 述评 • 上一篇    下一篇

眼科人工智能研究存在的主要问题及对策

王亚星1  薛灿灿1,2 李建军1   

  1. 1首都医科大学附属北京同仁医院 北京同仁眼科中心  北京市眼科研究所  眼科学与视觉科学北京市重点实验室1000052北京大学第三医院眼科100191

  • 收稿日期:2021-02-09 出版日期:2021-03-25 发布日期:2021-03-26
  • 通讯作者: 王亚星,Email:yaxingw@gmail.com
  • 基金资助:
    北京市属医学科研院所公益发展改革试点项目(2019-4)

Main problems and countermeasures of ophthalmic artificial intelligence research

Wang Yaxing1, Xue Cancan1,2, Li Jianjun1   

  1. 1Beijing Tongren Eye Center, Beijing Tongren Hospital,Beijing Institute of Ophthalmology, Capital Medical University; Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100005, China; 2 Department of Ophthalmology, the Third Hospital of Peking University, Beijing 100191, China

  • Received:2021-02-09 Online:2021-03-25 Published:2021-03-26
  • Contact: Wang Yaxing, Email: yaxingw@gmail.com
  • Supported by:

    Beijing Municipal of Health Reform and Development Project (2019-4)

摘要:

 人工智能(artificial intelligence,AI)技术与医学的结合是当前趋势,眼科学因丰富的影像资料成为研究热点。目前,关于糖尿病视网膜病变、年龄相关性黄斑变性及青光眼等常见致盲眼病已有较多AI研究,相关成果已逐步应用于临床实践,但同时面临许多挑战。就眼科及整个医疗领域而言,AI研究存在研究流程不规范、透明性及可重复性缺乏、结果报告不标准等问题,降低了AI研究的质量以及不同研究间的可比性,减缓了AI产品临床应用进程。本文概述眼部疾病AI研究现状及现存主要问题,并简要介绍当前医疗领域AI研究需遵循的标准和规范,旨在进一步规范眼科领域AI研究,促进AI技术与眼科高效结合及有效应用。(眼科,2021,30: 81-84)


关键词:

"> 人工智能;糖尿病视网膜病变;年龄相关性黄斑变性;青光眼;规范

Abstract:

 With the advent of artificial intelligence (AI) and its implication in medical field in recent years, AI in ophthalmology has been a trending topic. In case of major vision-threatening diseases, like diabetic retinopathy, glaucoma, and age-related macular degeneration, AI-related researches have emerged expansively. Despite much promising research currently being undertaken, general issues exist, like being lack of transparency, clear reporting to facilitate replicability, and clear demonstrations of effectiveness. This article described the challenges and unmet needs for AI application in major eye diseases and the common conditions in the field, and additionally introduced guidelines to regulate AI researches in ophthalmology and health care. (Ophthalmol CHN, 2021, 30: 81-84)


Key words:

artificial intelligence, diabetic retinopathy, age-related macular degeneration, glaucoma, standardization